Discovery/R&D

51. BoB@JPM: Academia To Industry With Oncolytics' Matt Coffey, Ph.D. 2/12/2023

    The JP Morgan Healthcare Conference is a target-rich environment for conversations with the leaders of up-and-coming biopharma companies, so we took the Business of Biotech on the road. On today's episode, we sat down with Matt Coffey, Ph.D., who earned his Ph.D. in 1998 and turned his doctoral thesis into a biopharma company called Oncolytics in 1999. Dr. Coffey shares on his abrupt transition from academia to industry, tells tales of the company's backstory, and updates us on its aggressive clinical activity spanning 7 wide-ranging oncology programs.

52. Biotech Collaboration Strategy With IGI's Cyril Konto, M.D. 11/20/2025

    On this week's Business Of Biotech episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million upfront licensing deal with AbbVie, the impact of China's rising biotech sector, and the keys to successful collaboration.

53. Academia + Industry with BridgeBio's Dr. Michael Henderson 6/21/2021

    BridgeBio has a whopping 30+ pre-clinical to clinical-stage candidates in its pipeline representing an impressive array of modalities and targets. It boasts a couple of commercial wins under its belt. The company is no stranger to developing business strategies for success. Central to that success are partnerships with scientists and researchers to fuel pipeline expansion. On this episode of The Business of Biotech, BridgeBio Chief Business Officer Michael Henderson, M.D. walks us through the formula behind the company's academia-led growth strategy.

54. Bacterial Therapy: Modulation Of The Microbiome 11/24/2020

    Dr. Bernat Olle, CEO joins The Business of Biotech to talk about the pioneering work that his company, Vedanta Biosciences, is doing to modulate the immune system and provide colonization resistance against infectious pathogens -- particularly those contracted during hospital stays. Learn about Dr. Olle's leadership of a company that's pioneering the exploration of immune-regulating and immune-potentiating bacteria that live in association with humans.

55. Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner, Ph.D. 4/10/2024

    Ampersand Biomedicines CEO Jason Gardner, Ph.D. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with the Flagship Pioneering-backed Ampersand, he's putting all those hard-fought lessons to good use.

56. Gene Tx For Hearing Loss With Sensorion's Nawal Ouzren 4/12/2023

    We often talk about biotechs taking "big swings." This week's guest is swinging for the fences with a lineup of gene therapies designed to address multiple forms of hearing loss, which affect multiple millions (if not, billions) of people worldwide. Adding to the challenge she's accepted, Sensorion CEO Nawal Ouzren is architecting an approach that seeks to restore hearing that's been lost due to genetic factors, treat sudden hearing disorders, and proactively prevent hearing loss due to common causes such as cisplatin induced ototoxicity or cochlear implantation. Listen in as Ouzren shares her holistic and aggressive plans with the Business of Biotech.

57. Inhalable mAbs & Vaccines With TFF's Glenn Mattes 12/6/2021

    Glenn Mattes' TFF Pharmaceuticals is looking to break the parenteral barrier by manufacturing biologics — mAbs and vaccines, more specifically — that can be inhaled, rather than injected. It's a timely endeavor, and TFF's business model is a collaborative one that seeks to explore dry powder biologic options through partnership, in addition to its own pipeline. On this episode of the Business of Biotech, the veteran biopharma CEO shares the company's vision and the technology that's bringing it into focus.

58. A Vaccine For Type 1 Diabetes With Diamyd Medical's Dr. Ulf Hannelius 7/19/2021

    As leaders at Diamyd Medical made plans to manufacture clinical supply of therapies aimed at preserving and restoring insulin production in Type 1 diabetes patients, outsourced production was on the table. Then, the company doubled down on its intentions and built out its own manufacturing facility. On this week's episode of The Business of Biotech, Diamyd Medical President & CEO Dr. Ulf Hannelius tells us all about the therapies his company is developing, plus the why and the how behind the company's choice to manufacture them in-house.

59. Multimodal R&D Management With Incyte's Jim Lee, M.D., Ph.D. 1/18/2024

    Success at multimodal, multi-indication, deep-pipelined Incyte—where commercial operations are as familiar as pre-discovery activity is—begins at the earliest opportunity to achieve research and discovery efficiencies.

60. COO Liftoff With Rocket Pharmaceuticals' Kinnari Patel, PharmD 7/12/2023

    Chief Operating Officer is arguably the toughest job in the emerging biopharma C-suite. HR, CMC, regulatory affairs, legal, PR, you name it, the COO touches it, and practically everything rolls up to her. This week's episode of the Business of Biotech brings us to a president and COO who's also a mom, a volunteer, and an advocate for diversity and equality in biopharma. That advocacy isn't just lip service, by the way. Here, Rocket Pharmaceuticals' Kinnari Patel, PharmD, shares on the real, practical, replicable steps Rocket takes to build a diverse and equitable work environment, how the fruits of that effort have proven important to the company's success, and where Rocket is taking its high-flying gene therapy act next.

    Subscribe to the NEW #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!